首页> 外文期刊>Molecular Psychiatry >Genome-wide significant risk factors for Alzheimer|[rsquo]|s disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment
【24h】

Genome-wide significant risk factors for Alzheimer|[rsquo]|s disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment

机译:全基因组阿尔茨海默氏病的重要危险因素:轻度认知障碍受试者在阿尔茨海默氏病所致痴呆中的作用

获取原文
           

摘要

Few data are available concerning the role of risk markers for Alzheimer’s disease (AD) in progression to AD dementia among subjects with mild cognitive impairment (MCI). We therefore investigated the role of well-known AD-associated single-nucleotide polymorphism (SNP) in the progression from MCI to AD dementia. Four independent MCI data sets were included in the analysis: (a) the German study on Aging, Cognition and Dementia in primary care patients (n=853); (b) the German Dementia Competence Network (n=812); (c) the Fundació ACE from Barcelona, Spain (n=1245); and (d) the MCI data set of the Amsterdam Dementia Cohort (n=306). The effects of single markers and combined polygenic scores were measured using Cox proportional hazards models and meta-analyses. The clusterin (CLU) locus was an independent genetic risk factor for MCI to AD progression (CLU rs9331888: hazard ratio (HR)=1.187 (1.054–1.32); P=0.0035). A polygenic score (PGS1) comprising nine established genome-wide AD risk loci predicted a small effect on the risk of MCI to AD progression in APOE-ε4 (apolipoprotein E-ε4) carriers (HR=1.746 (1.029–2.965); P=0.038). The novel AD loci reported by the International Genomics of Alzheimer's Project were not implicated in MCI to AD dementia progression. SNP-based polygenic risk scores comprising currently available AD genetic markers did not predict MCI to AD progression. We conclude that SNPs in CLU are potential markers for MCI to AD progression.
机译:在患有轻度认知障碍(MCI)的受试者中,关于阿尔茨海默氏病(AD)危险标志物在发展为AD痴呆中的作用的数据很少。因此,我们调查了著名的与AD相关的单核苷酸多态性(SNP)在从MCI到AD痴呆的过程中的作用。分析中包括四个独立的MCI数据集:(a)关于初级保健患者的衰老,认知和痴呆的德国研究(n = 853); (b)德国痴呆症能力网络(n = 812); (c)来自西班牙巴塞罗那的FundacióACE(n = 1245); (d)阿姆斯特丹痴呆队列的MCI数据集(n = 306)。使用Cox比例风险模型和荟萃分析测量单个标记和多基因组合得分的影响。 Clusterin(CLU)基因位点是MCI到AD进展的独立遗传危险因素(CLU rs9331888:危险比(HR)= 1.187(1.054-1.32); P = 0.0035)。由9个已建立的全基因组AD风险位点组成的多基因评分(PGS1)预测,APOE-ε4(载脂蛋白E-ε4)携带者对MCI发生AD进展的风险影响较小(HR = 1.746(1.029-2.965); P = 0.038)。国际老年痴呆症项目的基因组学报道的新型AD基因座与MCI到AD痴呆的进展无关。包含当前可用的AD遗传标记的基于SNP的多基因风险评分不能预测MCI到AD的进展。我们得出结论,CLU中的SNP是MCI到AD进展的潜在标志。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号